Participants 0 87 5
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Participants 533 868 7
The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment
